Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Volatility watch: Some of the volatility names to watch include Colony Capital (NYSE: CLNY ) , American Eagle Outfitters (NYSE: AEO ) and Brookfield Property Partners (NASDAQ: BPY ) with short interest positions on the rise. Virgin Galactic (NYSE: SPCE ) and National Beverage (NAS...
Assembly Biosciences (NASDAQ: ASMB ) : Q2 GAAP EPS of $0.19 misses by $0.03 . Revenue of $39.38M (+1178.6% Y/Y) in-line. Press Release More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news,
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results...
Deals and Financing Beijing's BeiGene (NSDQ: [[BGNE]]; HK: 06160) in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus ((HBV)) from Assembly Biosciences (NSDQ: [[ASMB]]) in a $540 million agreement. All three molecules have started US clinical trials. BeiGen...
BeiGene (NASDAQ: BGNE ) inks an agreement with Assembly Biosciences (NASDAQ: ASMB ) securing exclusive development and commercialization rights in Greater China (Mainland, Macau, Taiwan, Hong Kong) for ABI-H0731, ABI-H2158 and ABI-H3733, three clinical-stage core inhibitor candidates f...
-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China -- -- Assembly receives $40 million upfront payment and is eligible to receive up to $500 million in potential development, regulatory, and sales milestone paymen...
The FDA designates Assembly Biosciences' (NASDAQ: ASMB ) Phase 2-stage ABI-H2158, a second-generation core inhibitor, for Fast Track review for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Assembly Biosciences, Inc., Healthcare stocks news, Stocks on the move...
SOUTH SAN FRANCISCO, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S...
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of stock ...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...